Genmab A/S reaffirmed financial guidance for 2024. The company's revenue guidance is unchanged and expected to be in the previously disclosed guidance range of DKK 18.7 billion ? DKK 20.5 billion.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,798 DKK | -1.86% | -6.48% | -16.57% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.57% | 16.88B | |
+18.15% | 124B | |
+18.02% | 112B | |
+3.87% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B | |
+106.26% | 10.31B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab A/S Reaffirms Financial Guidance for 2024